Ervin Ruzics, MD
Transplant Surgery · Orange, CANPI 1285789149
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for transplant surgery clinicians in CA, where the typical reported total is $2,317.
Across 13 payments — averaging $24.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veloxis Pharmaceuticals, Inc.$75
- Takeda Pharmaceuticals U.S.A., Inc.$67
- Alnylam Pharmaceuticals Inc.$39
- Invivyd Inc$33
- Sanofi-aventis U.S. LLC$27
- Eurofins Viracor, LLC$21
- plus $54 from 3 others
What the payments were for
- Food & beverage$316100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veloxis Pharmaceuticals, Inc. | 3 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $67 |
| Alnylam Pharmaceuticals Inc. | 2 | $39 |
| Invivyd Inc | 1 | $33 |
| Sanofi-aventis U.S. LLC | 1 | $27 |
| Eurofins Viracor, LLC | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Exact Sciences | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
How this compares
$316 in reported general payments places this provider in the 25th percentile of 56 transplant surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tacrolimus | 33 | $2,921 |
| Valganciclovir Hcl | 17 | $2,263 |
| Tamsulosin Hcl | 37 | $324 |
| Mycophenolate Mofetil | 11 | $304 |
| Pantoprazole Sodium | 39 | $250 |
| Prednisone | 26 | $229 |
Paid to pharmacies, not to this prescriber.
Other transplant surgery in Orange
- Robert RedfieldOrange$65K
- Christina PapageorgeOrange$4K
- Caroline TranOrange$145
- Hirohito IchiiOrange$125
- Elizabeth SquiersHalf Moon Bay$1.3M
- Myron TongPasadena$99K
- Yuri GenykLos Angeles$35K
- Angeles Baquerizola Jolla$28K
- Navpreet KaurLos Angeles$19K
- Gerald LipshutzLos Angeles$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.